GREY:DGCRF - Post by User
Post by
ready2go1on May 19, 2010 11:54am
322 Views
Post# 17113629
The buy side
The buy sideI want to start off by saying that its a difficult market overall, but, its clear to see that interest has picked up on the bid. I have watched this develop over the past few weeks and if it has taught me anything, its how to be a patient buyer, sitting tight with my bid. Anyone who has followed this company for a period of time can see that a move is coming. Its a shame that we always have a tendency to dip prior to the move. We are around 10-15% lower than I would like us to be but there is no investor anticipation because no updates or expectations have been discussed. We can throw all of that out the window because in terms of expectations, Diagnocure has always done a poor job of keeping us informed and in terms of pca3, the blame is pushed to Gen-Probe because they keep CUR in the dark.
We have both AUA and ASCO coming up and I would think that this is a great opportunity to launch PCA3, creating a pre-FDA buzz. Prostate Cancer has been in the news for the past 6-8 months and physicians and patients are looking for solutions to their problems that have been discussed in great length in a number of Journals. PCA3 provides answers to many questions and comfort to patients who ask "what do I do next?" As a cancer patient myself, patients look to overcome obstacles, uncertainty, anxiety and the unknown which consumes and destroy their lives. Having any type of test that provides hope, something to hang your hat on and believe in, goes a long way to getting your life back on track and doing the things you want to do. We live in a society that has doubts and wants to see the proof. Did the biopsy tell me everything I need to know? well here is the PCA3 test to ease some of your fears and concerns.
I am going to take a little break from the board and come back once we move over the $3.00 mark. I am still looking for $2.00 in the next few weeks and think that there will a number of PCA3 drivers and also Diagnocure specific drivers to lift the share price well past our expectations.